- Home
- SSII vs IMNM Comparison
SSII vs IMNM Comparison
Compare SSII & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSII
- IMNM
- Stock Information
- Founded
- SSII N/A
- IMNM 2006
- Country
- SSII India
- IMNM United States
- Employees
- SSII N/A
- IMNM N/A
- Industry
- SSII
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- SSII
- IMNM Health Care
- Exchange
- SSII Nasdaq
- IMNM Nasdaq
- Market Cap
- SSII 1.4B
- IMNM 1.2B
- IPO Year
- SSII N/A
- IMNM 2020
- Fundamental
- Price
- SSII $9.98
- IMNM $16.52
- Analyst Decision
- SSII
- IMNM Strong Buy
- Analyst Count
- SSII 0
- IMNM 9
- Target Price
- SSII N/A
- IMNM $24.89
- AVG Volume (30 Days)
- SSII 135.5K
- IMNM 1.8M
- Earning Date
- SSII 11-14-2025
- IMNM 11-12-2025
- Dividend Yield
- SSII N/A
- IMNM N/A
- EPS Growth
- SSII N/A
- IMNM N/A
- EPS
- SSII N/A
- IMNM N/A
- Revenue
- SSII $27,623,624.00
- IMNM $12,589,000.00
- Revenue This Year
- SSII N/A
- IMNM N/A
- Revenue Next Year
- SSII N/A
- IMNM $140.06
- P/E Ratio
- SSII N/A
- IMNM N/A
- Revenue Growth
- SSII 134.89
- IMNM 16.74
- 52 Week Low
- SSII $2.48
- IMNM $5.15
- 52 Week High
- SSII $22.42
- IMNM $17.08
- Technical
- Relative Strength Index (RSI)
- SSII 71.93
- IMNM 71.76
- Support Level
- SSII $8.50
- IMNM $15.11
- Resistance Level
- SSII $10.00
- IMNM $17.08
- Average True Range (ATR)
- SSII 0.95
- IMNM 1.14
- MACD
- SSII 0.36
- IMNM 0.25
- Stochastic Oscillator
- SSII 99.47
- IMNM 90.36
About SSII SS Innovations International Inc.
SS Innovations International Inc is a commercial-stage surgical robotics company focused on transforming patient lives by democratizing access to advanced surgical robotics technologies. The company designs, manufactures, and markets an advanced, next-generation, and affordable surgical robotic system called the SSi Mantra, and the instruments and accessories used with SSi Mantra to perform a wide range of soft-tissue, robotically assisted surgeries. The company earns the majority of its revenue from India.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.